Physiology and Pharmacology

en Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphism in patients with schizophrenia Nervous system (others) Others Experimental research article Experimental research article Introduction: Hyperprolactinemia is a common serious side effect of antipsychotic medications that are currently used in the treatment of patients with schizophrenia. Pharmacogenetic approaches offer the possibility of identifying patient-specific biomarkers for predicting the risk of this side effect. We investigated a possible relationship between variants (SNPs) in genes for cytochrome 2D6 (CYP2D6), dopamine-2 receptor (DRD2) and serotonin-2C receptor (HTR2C) and antipsychotic drug-induced hyperprolactinemia in patients with schizophrenia. Methods: Overall, 128 Russian patients with paranoid schizophrenia (61F/67M, aged 18-65 y) were included. Serum prolactin concentration was measured with ELISA. DNA analysis and genotyping of CYP2D6 (rs3892097), DRD2 (rs6275) and HTR2C (rs6318) genes was done with StepOnePlus Real-Time PCR System using TaqMan® SNP Genotyping Assays (Applied Biosystems, USA). Results: Our study showed an association of the CYP2D6 (rs3892097) and HTR2C (rs6318) gene polymorphism with hyperprolactinemia in patients with schizophrenia on the background of therapy. No associations were identified between the DRD2 (rs6275) gene polymorphism and the risk of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Conclusion: Our study confirms a contribution of genetic factors to the antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Further studies are required to unravel the genetic predictors of antipsychotic-induced side effects and to develop the personalized treatment strategies for patients with schizophrenia. Schizophrenia, Hyperprolactinemia, Antipsychotics, Gene polymorphism 25 33 http://ppj.phypha.ir/browse.php?a_code=A-10-942-1&slc_lang=en&sid=1 Olga Yu. Fedorenko f_o_y@mail.ru 3200319475328460017373 3200319475328460017373 Yes Mental Health Research Institute, Tomsk NRMC, Russia Anton J.M. Loonen a.j.m.loonen@rug.nl 3200319475328460017374 3200319475328460017374 No Department of Pharmacy, University of Groningen, Groningen, The Netherlands Natalya M. Vyalova natarakitina@yandex.ru 3200319475328460017375 3200319475328460017375 No Mental Health Research Institute, Tomsk NRMC, Russia Аnastasiya S. Boiko anastasya-iv@yandex.ru 3200319475328460017376 3200319475328460017376 No Mental Health Research Institute, Tomsk NRMC, Russia Ivan V. Pozhidaev craig1408@yandex.ru 3200319475328460017377 3200319475328460017377 No Mental Health Research Institute, Tomsk NRMC, Russia Diana Z. Osmanova osmanovadiana@mail.ru 3200319475328460017378 3200319475328460017378 No Mental Health Research Institute, Tomsk NRMC, Russia Lyubov D. Rakhmazova 3200319475328460017379 3200319475328460017379 No Mental Health Research Institute, Tomsk NRMC, Russia Nikolay А. Bokhan bna909@gmail.com 3200319475328460017380 3200319475328460017380 No Mental Health Research Institute, Tomsk NRMC, Russia Mikhail V. Ivanov profmikhailivanov@gmail.com 3200319475328460017381 3200319475328460017381 No Bekhterev Psychoneurological Research Institute, St. Petersburg, Russia Maxim B. Freidin maxim.freydin@kcl.ac.uk 3200319475328460017382 3200319475328460017382 No Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom Svetlana А. Ivanova svetlana@mail.tomsknet.ru 3200319475328460017383 3200319475328460017383 No Mental Health Research Institute, Tomsk NRMC, Russia